CYP3A5 and cancer: Additionally, our investigation revealed the preferential expression of CYP3A5 in cancer cells expressing the GSC markers SOX2 and CD133 via co-immunofluorescence (co-IF) staining of human GBM surgical specimens (Fig. 2I).